ERYTECH Announces Launch of Investigator-Initiated Phase 2 Study of eryaspase (GRASPA®) for ALL

  • Post author:
  • Post category:Newsroom

ERYTECH today announced the launch of an investigator-initiated study to evaluate eryaspase, also known by the trade name GRASPA®, in patients with acute lymphoblastic leukemia (ALL). The study will take place in seven Nordic countries and be conducted in collaboration with the Nordic Society of Pediatric Hematology and Oncology (NOPHO).